{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:59:28Z","timestamp":1791907168882,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2022,4,5]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Plasma fibroblast growth factor 23 (FGF23) has been reported to be a predictive biomarker for therapeutic effectiveness of angiotensin\u2010converting enzyme inhibitors in heart failure. Higher plasma FGF23 levels have been shown in pediatric primary hypertension, but the predictive value of FGF23 for angiotensin\u2010converting enzyme inhibitors\u2019 effectiveness in pediatric primary hypertension has not been documented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              This is a prospective study. An exploratory study with 139 patients was first conducted to determine the cutoff value of FGF23 for the prediction of treatment responsiveness. After receiving fosinopril for 4\u00a0weeks, of all 139 patients, 91 responded, while 48 did not respond to the treatment, and the responders had a significantly higher baseline plasma FGF23 level than nonresponders (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.01). Multiple regression analysis revealed a significant impact of baseline plasma FGF23 levels on fosinopril responsiveness (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.05). The receiver operating characteristic curve analysis showed that the plasma FGF23 predicted the effectiveness of fosinopril treatment with an area under the curve of 0.784 (95% CI, 0.704\u20130.863) for a sensitivity and a specificity of 67.0% and 89.6%, respectively, for a cutoff value of 62.08\u00a0RU\/mL. Subsequently, another group of 40 patients were recruited for validation. The blood pressure control rate in those (n=22) with baseline plasma FGF23 &gt;62.08\u00a0RU\/mL was significantly higher than that in children (n=18) with FGF23 \u226462.08\u00a0RU\/mL (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.05).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">Plasma FGF23 might be a valuable biomarker to guide fosinopril therapy for primary hypertension in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.121.023182","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:39:30Z","timestamp":1648161570000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Fibroblast Growth Factor 23 as a Predictor for Fosinopril Therapeutic Efficacy in Pediatric Primary Hypertension"],"prefix":"10.1161","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-9194","authenticated-orcid":false,"given":"Yao","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Cardiology Children\u2019s Hospital Capital Institute of Pediatrics Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxi","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cardiology Children\u2019s Hospital Capital Institute of Pediatrics Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Cardiology Beijing Children\u2019s HospitalCapital Medical UniversityNational Center for Children\u2019s Health Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology Beijing Children\u2019s HospitalCapital Medical UniversityNational Center for Children\u2019s Health Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-8240","authenticated-orcid":false,"given":"Qirui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology Beijing Children\u2019s HospitalCapital Medical UniversityNational Center for Children\u2019s Health Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Huang","sequence":"additional","affiliation":[{"name":"Central Diagnostic Laboratory Children\u2019s Hospital Capital Institute of Pediatrics Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology Children\u2019s Hospital Capital Institute of Pediatrics Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-7440","authenticated-orcid":false,"given":"Lin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiology Children\u2019s Hospital Capital Institute of Pediatrics Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11673"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2018.09.001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.05.012"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00135"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30098-1"},{"key":"e_1_3_2_7_2","first-page":"1","article-title":"Fibroblast growth factor 23\u2010Klotho and hypertension: experimental and clinical mechanisms","volume":"23","author":"Freundlich M","year":"2020","unstructured":"Freundlich M, Gamba G, Rodriguez\u2010Iturbe B. Fibroblast growth factor 23\u2010Klotho and hypertension: experimental and clinical mechanisms. Pediatr Nephrol. 2020;23:1\u201316. doi: 10.1007\/s00467\u2010020\u201004843\u20106","journal-title":"Pediatr Nephrol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.S2.555"},{"key":"e_1_3_2_10_2","first-page":"182","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension\u2010a report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension","volume":"16","author":"Joint Committee for Guideline Revision","year":"2019","unstructured":"Joint Committee for Guideline Revision . 2018 Chinese guidelines for prevention and treatment of hypertension\u2010a report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16:182\u2013241. doi: 10.11909\/j.issn.1671\u20105411.2019.03.014","journal-title":"J Geriatr Cardiol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14168"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000138069.68413.f0"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-310582"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00333"},{"key":"e_1_3_2_15_2","first-page":"721","article-title":"Impact of serum FGF23 levels on blood pressure of patients with chronic kidney disease","volume":"22","author":"Li JX","year":"2018","unstructured":"Li JX, Yu GQ, Zhuang YZ. Impact of serum FGF23 levels on blood pressure of patients with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2018;22:721\u2013725. doi: 10.26355\/eurrev_201802_14299","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.332"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000294"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000936"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11060"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303716"},{"key":"e_1_3_2_21_2","first-page":"229","article-title":"FGF23 promotes renal calcium reabsorption through the TRPV5 channel","volume":"33","author":"Andrukhova O","year":"2014","unstructured":"Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, Shalhoub V, Mohammadi M, Pohl EE, Lanske B, et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 2014;33:229\u2013246. doi: 10.1002\/embj.201284188","journal-title":"EMBO J"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044161"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184634"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy006"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0078-3"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.06.027"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.12.010"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.906489"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1127-7"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.121.023182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:28:48Z","timestamp":1715599728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.121.023182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,5]]}},"alternative-id":["10.1161\/JAHA.121.023182"],"URL":"https:\/\/doi.org\/10.1161\/jaha.121.023182","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"2021-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e023182"}}